Bausch Health Companies Inc. (BHC) has expanded its medical aesthetics portfolio in Canada with the launch of the Clear + Brilliant Touch laser, a dual‑wavelength fractional laser that delivers skin resurfacing and soft‑tissue coagulation for a wide range of skin types and ages. The device received Health Canada approval on May 20, 2025, and the Canadian launch took place on February 23, 2026.
The Clear + Brilliant Touch builds on Solta Medical’s established Clear + Brilliant platform, which entered the U.S. market in March 2021. By adding the Touch version to its lineup, Solta expands its product mix to include a more versatile, shorter‑treatment option that can be used in both office and clinic settings. The launch is part of Solta’s broader international expansion strategy, which has seen significant growth in markets such as South Korea, China, and the United States.
Financially, Solta Medical has been a key growth engine for Bausch Health. In Q1 2025, Solta generated $113 million in revenue, a 28% year‑over‑year increase driven largely by strong demand in Asia Pacific. The segment reported $137 million in Q4 2025, a slight 1% decline on a reported basis but flat on an organic basis, underscoring the resilience of its core markets. Bausch Health’s overall 2025 consolidated revenue reached $10.27 billion, up 7% from the prior year, with Solta Medical contributing a significant share of the growth.
The Canadian launch is expected to generate incremental sales and consumable revenue over the coming years, although it will not have an immediate impact on quarterly earnings. The addition of the Clear + Brilliant Touch laser positions Solta to capture a larger share of Canada’s growing non‑invasive skin rejuvenation market, which is projected to expand as consumer demand for minimally invasive aesthetic procedures rises. By broadening its device portfolio, Bausch Health strengthens its strategy to diversify beyond its core pharmaceutical businesses and enhance its high‑margin medical device revenue streams.
Bausch Health’s management has highlighted Solta Medical’s role in the company’s long‑term growth strategy. The company’s 2025 financial results showed consistent revenue and adjusted EBITDA growth, with Solta Medical being a key contributor. The launch aligns with Bausch Health’s ongoing efforts to reduce debt and invest in high‑margin growth areas, reinforcing its commitment to expanding its non‑pharma footprint.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.